The Heifets Laboratory
Welcome to the Heifets Lab
Our research group is dedicated to understanding and improving on powerful, rapid-acting therapies for psychiatric disease, such as ketamine, MDMA and psilocybin. We bridge basic science and clinical trials, connecting neuroscience, psychiatry and anesthesiology in pursuit of highly effective, safe treatment strategies scalable to the millions of patients who need them.
Follow Us on Twitter
Great to see replications of studies in this field! In this more rigorous set of studies, the findings from the original study showing a reduction in authoritarian attitudes after psychedelics was not observed.
Now out in JoP with @zarmeen_z and Rick Strassman: 5HT-1A blockade with pindolol increases the subjective effects of DMT.
This is the first quantitative analysis of 1A blockade on a psychedelic in humans., from data previously collected by Strassman but never analyzed
I spoke with Peter Hendricks about his fascinating psilocybin for cocaine use disorder study, out today.
Aside from the impressively representative patient population and positive result, there was also a report of spontaneous orgasm!
Full interview (no paywall)...
When I saw the news about the new executive order to fast-track psychedelic clinical trials and devote more $$$ to psychedelics research, I knew just who to call. Thanks, @TheBorisLab, for walking us through the policy and the science and sharing a peak into your crystal ball!
The federal government is fast-tracking psychedelic clinical trials for mental health.
Stanford anesthesiologist Boris Heifets @TheBorisLab joins us to discuss psilocybin, ibogaine, clinical trials, and the evolving landscape of psychedelic medicine.
https://neuroscience.stanford.edu/news/fdas-psychedelic-sea-change-what-it-means-mental-health-and-neuroscience-research
“We found that psilocybin plus psychotherapy elicits more cocaine abstinence compared to placebo plus psychotherapy. Specifically, those who received psilocybin reported more days of abstinence, a greater likelihood of complete abstinence, and longer time to first lapse after
Honored that our paper was selected as one of the top clinical trials of the year! Hopefully just the beginning in revamping surgical outcomes for our amazing patients!
Editor's Choice: Clinical Trials of the Year
Explore clinical trials selected by JAMA Network journal editors for their interest, impact, or innovation.
jamanetwork.com
Happy to share our (@sdpnayak @rick_strassman & Cliff Quals) new publication titled "5-HT1A receptor blockade potentiates the subjective effects of DMT" which is a bayesian analysis of previously collected data by @rick_strassman
5-HT1A receptor blockade potentiates the subjective effects of DMT - Zarmeen Zahid, Rick J....
Introduction: Serotonergic psychedelics are being investigated in the treatment of various disorders and in the improvem...
journals.sagepub.com
Looking forward to a lively discussion on this work today. Please stop by Poster S217 — I’d love to connect!